Search results for "Antipsychotic"

showing 10 items of 189 documents

Binding of several phenothiazine neuroleptics to a common binding site of alpha 1-acid glycoprotein, orosomucoid.

1983

The interaction of several phenothiazine neuroleptics with alpha 1-acid glycoprotein was investigated using circular dichroism and equilibrium dialysis techniques. For chlorpromazine only, one high-affinity binding site of the protein was found. The binding of the drug to this single site generated typical polyphasic extrinsic Cotton effects. Since several other phenothiazine neuroleptics gave qualitatively comparable extrinsic Cotton effects in the presence of alpha 1-acid glycoprotein and potently inhibited the binding of chlorpromazine to the single site, it was concluded that all phenothiazine derivatives investigated bound preferentially to only one common binding site of the alpha 1-a…

Circular dichroismStereochemistryPharmaceutical ScienceOrosomucoidchemistry.chemical_compoundStructure-Activity RelationshipSingle sitePhenothiazinesPhenothiazinemedicineHumansBinding siteChlorpromazinechemistry.chemical_classificationBinding SitesbiologyChemistryCircular DichroismOrosomucoidBiochemistryα1 acid glycoproteinbiology.proteinGlycoproteinDialysismedicine.drugAntipsychotic AgentsProtein BindingJournal of pharmaceutical sciences
researchProduct

In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic chang…

2011

Abstract Background P-glycoprotein (P-gp), an efflux transporter of the blood–brain barrier, limits the access of multiple xenobiotics to the central nervous system (CNS). Thus drug-dependent inhibition, induction or genetic variation of P-gp impacts drug therapy. Methods We investigated atypical antipsychotics and their interaction with P-gp. Amisulpride, clozapine, N-desmethylclozapine, olanzapine, and quetiapine were assessed in vitro on their inhibitory potential and in vivo on their disposition in mouse serum and brain, and behaviourally on the RotaRod test. In vivo wildtype (WT) and mdr1a/1b double knockout mice (mdr1a/1b (−/−, −/−); KO) were investigated. Results In rhodamine 123 eff…

Clinical BiochemistryIn Vitro TechniquesPharmacologyToxicologyBlood–brain barrierBiochemistryRhodamine 123Rotarod performance testMiceBehavioral Neurosciencechemistry.chemical_compoundPharmacokineticsIn vivoCell Line TumormedicineAnimalsRhodamine 123ATP Binding Cassette Transporter Subfamily B Member 1Biological PsychiatryClozapineP-glycoproteinMice KnockoutPharmacologybiologyReceptors Dopamine D2Protein Transportmedicine.anatomical_structurechemistryRotarod Performance Testbiology.proteinDopamine AntagonistsEffluxAntipsychotic Agentsmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Tratamiento psicofarmacológico del trastorno bipolar en América Latina

2011

Objective: This study assessed the treatment preferences among Latin-American psychiatrists for their bipolar disorder patients and if these preferences reflect the current guidelines. Methods: We designed a survey comprised of fourteen questions. All the questions were aimed at the treatment of bipolar I patients only. We distributed the survey by hand or e-mail to psychiatrists in eight different countries: Argentina, Brasil, Colombia, Costa Rica, Ecuador, México, Perú and Venezuela. Between May 2008 and June 2009, we were able to gather 1143 surveys. Results: As the initial choice of treatment for a bipolar patient who debuts with mania, 61.3% choose a combination of an atypical antipsyc…

Costa RicaBipolar Disorder//purl.org/pe-repo/ocde/ford#3.02.24 [https]ArgentinaAtypical Antipsychotic AgentColombiaLamotrigineLithium CarbonatePsychopharmacotherapyPeruMood StabilizerAntidepressant AgentPatternsMexicoDrug ChoiceVenezuelaTreatmentPsychiatry and Mental healthManiaOlanzapineAcute DiseaseBipolarLatin-AmericaEcuadorSouth And Central AmericaBrazil
researchProduct

Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromat…

2001

An automated method for simultaneous routine quantification of the antipsychotic drugs clozapine, olanzapine and their demethylated metabolites is described. The method included adsorption on a cyanopropyl (CPS) coated clean-up column (10 microm; 10 x 2.0 mm I.D.), washing off interfering serum constituents to waste, and separation on C18 ODS Hypersil reversed phase material (5 microm; 250 x 4.6 mm I.D.) using acetonitrile-water-tetramethylethylenediamine (37:62.6:0.4, v/v/v) adjusted to pH 6.5 with concentrated acetic acid. UV-detection was performed at 254 nm. The limit of quantification was 10-20 ng/ml. Relative day to day standard variations ranged between 4.5 and 13.5%. The method is s…

Detection limitChromatographyChemistryMetaboliteReproducibility of ResultsGeneral ChemistryPirenzepineHigh-performance liquid chromatographySensitivity and SpecificityAcetic acidchemistry.chemical_compoundBenzodiazepinesAdsorptionPharmacokineticsOlanzapinemedicineHumansSpectrophotometry UltravioletQuantitative analysis (chemistry)ClozapineClozapineChromatography High Pressure Liquidmedicine.drugAntipsychotic AgentsJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spe…

2004

Abstract An automated HPLC method with column switching is described for the determination of quetiapine, clozapine, perazine, olanzapine and metabolites in blood serum. After clean-up on silica C8 material (20 μm particle size) drugs were separated on ODS Hypersil C18 material (5 μm; column size 250 mm × 4.6 mm i.d.) within 25 min and quantified by ultraviolet (UV) detection at 254 nm. The limit of quantification ranged between 10 and 50 ng/ml. At therapeutic concentrations of the drugs, the inter-assay reproducibility was below 10%. Analyses of drug concentrations in serum of 75–295 patients treated with therapeutic doses of the antipsychotic drugs revealed mean ± S.D. steady state concen…

DrugDibenzothiazepinesmedicine.drug_classmedia_common.quotation_subjectClinical BiochemistryAtypical antipsychoticPharmacologyBiochemistryHigh-performance liquid chromatographyAnalytical ChemistryPerazineBenzodiazepinesQuetiapine FumarateColumn chromatographyBlood serummedicineHumansClozapineChromatography High Pressure Liquidmedia_commonChromatographymedicine.diagnostic_testChemistryReproducibility of ResultsCell BiologyGeneral MedicinePerazineTherapeutic drug monitoringOlanzapineCalibrationQuetiapineSpectrophotometry Ultravioletmedicine.drugAntipsychotic AgentsJournal of chromatography. B, Analytical technologies in the biomedical and life sciences
researchProduct

Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.

2016

Second-generation antipsychotics (SGAs) are frequently co-prescribed with drug metabolic inducers and inhibitors. SGA pharmacokinetic drug-drug interactions (DDIs) with inducers and inhibitors have not received enough attention in the literature but can be studied in by using therapeutic drug monitoring (TDM).The limited information available on oral SGA pharmacokinetic DDIs is reviewed. A systematic literature search on the available oral SGA TDM studies is completed. By integrating TDM studies with the information on in vitro metabolism studies, case report/series and prospective studies, a table is provided to manage average SGA patients taking inducers or inhibitors by using TDM and/or …

DrugDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjecttherapeutic drug monitoringAdministration OralPharmacologyToxicology030226 pharmacology & pharmacyDrug interactions03 medical and health sciences0302 clinical medicinePharmacokineticsinhibitorsMedicineHumansProspective cohort studyClozapinemedia_commonLurasidoneinducersPharmacologyRisperidonemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industrysecond-generation antipsychoticsGeneral MedicineDrug interactions; inducers; inhibitors; pharmacokinetics; second-generation antipsychotics; therapeutic drug monitoring030227 psychiatryTherapeutic drug monitoringQuetiapineAntidepressive Agents Second-GenerationDrug Monitoringbusinesspharmacokineticsmedicine.drugAntipsychotic Agents
researchProduct

Distribution of clozapine and desmethylclozapine between blood and brain in rats.

1999

Desmethylclozapine is the major metabolite of clozapine in serum. Although the metabolite is pharmacologically active in vitro, the occurrence of desmethylclozapine in brain under steady-state conditions and its role for clinical actions of clozapine are unclear. In this study 20 male Sprague-Dawley rats received five oral doses of clozapine 20 mg/kg at 1.5-h intervals. At 0.5, 1, 2 and 5 h after the last administration, at a time four animals were killed for analysis of clozapine and desmethylclozapine concentrations in serum and brain. The treatment yielded steady-state serum concentrations of clozapine that are considered as therapeutically effective in man. Desmethylclozapine concentrat…

DrugMalemedia_common.quotation_subjectMetaboliteDesmethylclozapinePharmacologyRats sprague dawleyRats Sprague-Dawleychemistry.chemical_compoundMedicineDistribution (pharmacology)AnimalsPharmacology (medical)ClozapineBiological PsychiatryClozapineBiotransformationChromatography High Pressure Liquidmedia_commonPharmacologybusiness.industryBrainDrug applicationSerum concentrationRatsPsychiatry and Mental healthNeurologychemistryNeurology (clinical)businessmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Therapeutic Monitoring of Aripiprazole by HPLC with Column-Switching and Spectrophotometric Detection

2005

Aripiprazole is a novel atypical antipsychotic drug for the treatment of schizophrenia and schizoaffective disorders (1)(2)(3). The drug is metabolized by the cytochrome P450 isoenzymes 3A4 and 2D6 (4). Because of high interindividual variability in the expression of these enzymes, the aripiprazole concentration varies among healthy individuals after administration of the drug (5). In patients, insufficient response or side effects, such as somnolence, akathisia, or nausea, may result from too low or too high drug concentrations. Therapeutic drug monitoring (TDM), which is established practice for many antipsychotic drugs (6)(7), may be helpful for patients treated with aripiprazole. We mea…

DrugPerphenazinemedicine.drug_classmedia_common.quotation_subjectClinical BiochemistryAripiprazoleAtypical antipsychoticQuinolonesPharmacologyPartial agonistHigh-performance liquid chromatographyPiperazinesmedicineHumansChromatography High Pressure Liquidmedia_commonmedicine.diagnostic_testChemistryReboxetineBiochemistry (medical)Therapeutic drug monitoringSchizophreniaSpectrophotometry UltravioletAripiprazoleDrug MonitoringAntipsychotic Agentsmedicine.drugClinical Chemistry
researchProduct

Calixarene: A Versatile Material for Drug Design and Applications

2016

The therapy of various diseases by the drugs entrapped in calixarene derivatives is gaining attraction of researchers nowadays. Calixarenes are macrocyclic nano-baskets which belong to cavitands class of host-guest chemistry. They are the marvelous hosts with distinct hydrophobic three dimensional cavities to entrap and encapsulate biologically active guest drugs. Calixarene and its derivatives develop inclusion complexes with various types of drugs and vitamins for their sustained/targeted release. Calixarene and its derivatives are used as carriers for anti-cancer, anti-convulsant, anti-hypertensive, anthelmentic, anti-inflammatory, antimicrobial and antipsychotic drugs. They are the impo…

Drugmedia_common.quotation_subjectAnti-Inflammatory AgentsSupramolecular chemistrymacromolecular substances010402 general chemistry01 natural sciencesAnti-Infective AgentsDrug DiscoveryCalixareneHumansOrganic chemistryProdrugsAntihypertensive AgentsTargeted releasemedia_commonAnthelminticsPharmacologyDrug Carriers010405 organic chemistryChemistryProdrugBiocompatible material0104 chemical sciencesDrug DesignDrug releaseAnticonvulsantsCalixarenesAntipsychotic AgentsCurrent Pharmaceutical Design
researchProduct

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

2010

Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decrea…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceP-glycoproteinPharmacologyArticlelcsh:Pharmacy and materia medicaPharmacokineticsMedicineAntipsychoticDexamethasoneActive metaboliteP-glycoproteinmedia_commonrisperidoneRisperidonebiologybusiness.industryTransporterdrug transporterantipsychoticsdispositionbiology.protein9-hydroxyrisperidonebusinessmedicine.drugPharmaceutics
researchProduct